keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant therapy

keyword
https://www.readbyqxmd.com/read/28229358/postmastectomy-radiation-therapy-and-breast-reconstruction-with-autologous-tissue
#1
Yasunobu Terao, Koichiro Taniguchi, Miwako Fujii, So Moriyama
Immediate breast reconstruction is an important tool for patients to accept and overcome their breast cancer, as well as for cosmetic reasons. However, its use in patients who require postmastectomy radiation therapy (PMRT) is not yet clear. The purpose of this study was to analyze the effects of PMRT and reconstruction on each other. The time of initiation of PMRT, the prognosis, and the cosmetic results were investigated in patients who underwent immediate reconstruction using autologous tissue. In the case of delayed reconstruction using autologous tissue after PMRT, radiation damage of the chest skin, design of the flap, and cosmetic results were investigated...
February 22, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28229077/surgical-therapy-of-cholangiocarcinoma
#2
REVIEW
Arnold Radtke, Alfred Königsrainer
BACKGROUND: The majority of patients with cholangiocarcinoma present with advanced disease that is often challenging to diagnose and to treat. The optimal preoperative evaluation requires a coordinated multidisciplinary approach. Surgical resection is the mainstay of therapy. METHODS: This systematic review delineates surgical treatment strategies for cholangiocarcinoma in general as well as special considerations concerning the particular tumor localization. A literature search (see keywords) was conducted using PubMed and publications between 1990 and 2016 regarding resectable and advanced cholangiocarcinoma were reviewed...
December 2016: Visceral Medicine
https://www.readbyqxmd.com/read/28228705/her2-orientated-therapy-in-early-and-metastatic-breast-cancer
#3
REVIEW
Severine Iborra, Elmar Stickeler
Due to the enhanced understanding of molecular oncology and signaling pathways in breast cancer (BC), therapy management has undergone a major transformation, especially with the emergence of treatment tailored to individual disease characteristics. In the case of HER2-positive early or metastatic BC, targeted therapies are well established and remain a major focus of ongoing research. The introduction of anti-HER2 biologicals such as trastuzumab, pertuzumab, and T-DM1 has made targeted and personalized treatment possible and has clearly improved disease-free and overall survival in patients with HER2-positive BC...
December 2016: Breast Care
https://www.readbyqxmd.com/read/28228219/-analysis-of-efficacy-of-surgical-treatment-for-iiia-small-cell-lung-cancer
#4
Xuejun Dou, Zhiyuan Wang, Liang Wang, Weiqiang Lu, Yunlei Ma, Shaofa Xu
BACKGROUND: Small cell lung cancer (SCLC) accounts for nearly 15% of all cases of cancer. As a type of highly invasive tumors, SCLC has high degree of malignancy, early and extensive metastasis, and is sensitive to chemotherapy and radiotherapy. The early treatment response rate of SCLC is high but it can also relapse rapidly without any treatment. Its median survival time is merely four to six months. Although many studies on SCLC have been conducted in recent years, its clinical treatment strategies have remained unchanged...
February 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28228123/the-effects-of-exercise-on-pain-fatigue-insomnia-and-health-perceptions-in-patients-with-operable-advanced-stage-rectal-cancer-prior-to-surgery-a-pilot-trial
#5
Jennifer Brunet, Shaunna Burke, Michael P W Grocott, Malcolm A West, Sandy Jack
BACKGROUND: Promoting quality of life (QoL) is a key priority in cancer care. We investigated the hypothesis that, in comparison to usual care, exercise post-neoadjuvant chemoradiation therapy/prior to surgical resection will reduce pain, fatigue, and insomnia, and will improve physical and mental health perceptions in patients with locally advanced stage rectal cancer. METHODS: In this non-randomized controlled pilot trial, patients in the supervised exercise group (EG; M age = 64 years; 64% male) and in the control group (CG; M age = 72 years; 69% male) completed the European Organization for Research and Treatment of Cancer core Quality of Life questionnaire and the RAND 36-Item Health Survey three times: pre-neoadjuvant chemoradiation therapy (Time 1; n EC = 24; n CG = 11), post-neoadjuvant chemoradiation therapy/pre-exercise intervention (Time 2; n EC = 23; n CG = 10), and post-exercise intervention (Time 3; n EC = 22; n CG = 10)...
February 23, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28224384/swedish-prospective-multicenter-trial-evaluating-sentinel-lymph-node-biopsy-after-neoadjuvant-systemic-therapy-in-clinically-node-positive-breast-cancer
#6
Linda Holmstrand Zetterlund, Jan Frisell, Athanasios Zouzos, Rimma Axelsson, Thomas Hatschek, Jana de Boniface, Fuat Celebioglu
PURPOSE: Patients with clinically node-positive breast cancer planned for neoadjuvant systemic therapy (NAST) may draw advantages from the nodal downstaging effect and reduce the extent of axillary surgery with sentinel lymph node biopsy (SLNB) performed after NAST. Since there are concerns about lower sentinel lymph node (SLN) detection and higher false-negative rates (FNR) in this setting, our aim was to define the accuracy of SLNB after NAST. METHODS: This Swedish national multicenter trial prospectively recruited 195 breast cancer patients from ten hospitals with T1-T4d biopsy-proven node-positive disease planned for NAST between October 1, 2010 and December 31, 2015...
February 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28222973/nationwide-multi-institutional-retrospective-analysis-of-high-dose-rate-brachytherapy-combined-with-external-beam-radiotherapy-for-localized-prostate-cancer-an-asian-prostate-hdr-bt-consortium
#7
Hiromichi Ishiyama, Nobuhiko Kamitani, Hidemasa Kawamura, Shingo Kato, Manabu Aoki, Shinji Kariya, Taisei Matsumura, Motoki Kaidu, Ken Yoshida, Yaichiro Hashimoto, Yasutaka Noda, Keith H C Lim, Takatsugu Kawase, Takeo Takahashi, Koji Inaba, Motoyasu Kumano, Nobuhiko Yoshikawa, Yasuo Yoshioka, Katsumasa Nakamura, Junichi Hiratsuka, Jun Itami, Kazushige Hayakawa
PURPOSE: To report outcomes and risk factors of high-dose-rate (HDR) brachytherapy combined with external beam radiotherapy with or without androgen deprivation therapy (ADT) in prostate cancer patients. MATERIALS AND METHODS: This multi-institutional retrospective analysis comprised 3424 patients with localized prostate cancer at 16 Asian hospitals. One-thirds (27.7%) of patients received only neoadjuvant ADT, whereas almost half (49.5%) of patients received both neoadjuvant and adjuvant ADT...
February 17, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28218038/postoperative-human-epididymis-protein-4-predicts-primary-therapy-outcome-in-advanced-epithelial-ovarian-cancer
#8
Tuulia Vallius, Johanna Hynninen, Annika Auranen, Jaakko Matomäki, Sinikka Oksa, Pia Roering, Seija Grènman
Primary chemotherapy treatment response monitoring in advanced epithelial ovarian cancer (EOC) is currently based on CT-imaging and serum CA125 values. Serum HE4 profile during first line chemotherapy has not been previously studied. We evaluated the HE4 profile during first line chemotherapy after primary (PDS) and interval debulking surgery (IDS). In total, 49 FIGO stage III/IV EOC patients were included in the study. 22 patients underwent PDS and 27 patients neoadjuvant chemotherapy (NACT) followed by IDS...
February 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28217753/lymphadenectomy-state-of-the-art
#9
REVIEW
Daniele Marrelli, Lorenzo De Franco, Livio Iudici, Karol Polom, Franco Roviello
The extent of lymphadenectomy in gastric cancer (GC) surgery has been for long time a matter of debate. Randomized trials performed in the West reported worse results of D2 dissection, in terms of postoperative complications and long-term survival benefit, than Eastern series and observational studies from specialized Western centers. However, long-term re-evaluation of such trials and in depth-analysis of other experiences demonstrated the potential benefit of D2 in reducing the probability of cancer-related death and the safety of this procedure when avoiding unnecessary spleno-pancreatectomy and in centers with ad adequate surgical volume...
2017: Transl Gastroenterol Hepatol
https://www.readbyqxmd.com/read/28216450/an-evaluation-of-the-timing-of-surgical-complications-following-radical-cystectomy-data-from-the-american-college-of-surgeons-national-surgical-quality-improvement-program-acs-nsqip
#10
Akshay Sood, Naveen Kachroo, Firas Abdollah, Jesse D Sammon, Björn Löppenberg, Tarun Jindal, Maxine Sun, Quoc-Dien Trinh, Mani Menon, James O Peabody
OBJECTIVES: To examine time-to-event data for 19 common postoperative complications within 30 days following radical cystectomy (RC). METHODS: Patients undergoing RC were identified within the ACS-NSQIP database (2005-2011). The primary endpoint was time-to-complication; secondary endpoints included length-of-stay (LOS), re-intervention, readmission and 30-day mortality. Further, the complications were stratified into pre-/post-discharge and the predictors were identified...
February 16, 2017: Urology
https://www.readbyqxmd.com/read/28215851/a-novel-neoadjuvant-therapy-for-operable-locally-invasive-non-small-cell-lung-cancer-phase-i-study-of-neoadjuvant-stereotactic-body-radiotherapy-linnearre-i-nct02433574
#11
Nhu-Tram A Nguyen, Naghmeh Isfahanian, Gregory Pond, Wael Hanna, Jean-Claude Cutz, James Wright, Anand Swaminath, Yaron Shargall, Tom Chow, Marcin Wierzbicki, Gordon Okawara, Kimmen Quan, Christian Finley, Rosalyn Juergens, Theodoros Tsakiridis
BACKGROUND: Despite improved staging and surgical techniques, the rate of incomplete resection (R1) of non-small-cell lung cancer (NSCLC) has not significantly decreased. Patients with R1 resection have worse survival compared with those with complete resection (R0). Stereotactic body radiotherapy (SBRT) is a rapid and convenient radiotherapy treatment that delivers high-dose radiotherapy to tumors with high precision while sparing normal organs. Although its efficacy in treating small lung tumors is documented, its use as neoadjuvant therapy for locally advanced (LA) NSCLC has not been examined...
January 31, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28214145/effect-of-reduction-mammoplasty-on-acute-radiation-side-effects-and-use-of-lumpectomy-cavity-boosts
#12
Jolinta Y Lin, Rachel Bluebond-Langner, Enid Choi, Sally Cheston, Elizabeth M Nichols, Randi J Cohen, Soren M Bentzen, Cynthia Drogula, Susan Kesmodel, Emily Bellavance, Paula Rosenblatt, Katherine Tkaczuk, Sheri Slezak, Steven J Feigenberg
PURPOSE: Reduction mammoplasty (RM) during breast-conserving surgery is popular among women with large-volume breasts because it reduces redundant breast folds and may decrease skin-related morbidity from radiation therapy. However, RM may obscure the lumpectomy cavity (LC) and pose challenges to administering an LC boost, potentially affecting local control. We investigated the impact of RM on acute side effects and use of LC boosts. METHODS AND MATERIALS: The records of 645 consecutive women treated with whole-breast irradiation at an urban university and 2 community practices between January 2012 and December 2014 were reviewed on an institutional review board-approved study...
January 7, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28213801/efficacy-of-a-neoadjuvant-gonadotropin-releasing-hormone-antagonist-plus-low-dose-estramustine-phosphate-in-high-risk-prostate-cancer-a-single-center-study
#13
Kazuhisa Hagiwara, Takuya Koie, Chikara Ohyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Yuki Tobisawa, Tohru Yoneyama
PURPOSE: The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) for high-risk Pca patients treated with neoadjuvant therapy comprising a luteinizing hormone-releasing hormone agonist plus low-dose estramustine (LHRH + EMP) prior to radical prostatectomy (RP). In the present study, we evaluated the efficacy of neoadjuvant therapy comprising a gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate (GnRH + EMP) in patients with high-risk Pca...
February 17, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28213781/swedish-prospective-multicenter-trial-on-the-accuracy-and-clinical-relevance-of-sentinel-lymph-node-biopsy-before-neoadjuvant-systemic-therapy-in-breast-cancer
#14
Linda Zetterlund, Fuat Celebioglu, Rimma Axelsson, Jana de Boniface, Jan Frisell
PURPOSE: The timing of sentinel lymph node biopsy (SLNB) in the context of neoadjuvant systemic therapy (NAST) in breast cancer is still controversial. SLNB before NAST has been evaluated in few single-institution studies in which axillary lymph node dissection (ALND), however, was commonly not performed in case of a negative SLNB. We investigated the potential clinical relevance of SLNB before NAST by performing ALND in all patients after NAST. METHODS: This national multicenter trial prospectively enrolled clinically node-negative breast cancer patients planned for NAST at 13 recruiting Swedish hospitals between October 2010 and December 2015...
February 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28212363/vegf-inhibitors-in-renal-cell-carcinoma
#15
Pankit Vachhani, Saby George
The arrival of targeted therapies-vascular endothelial growth factor (VEGF) pathway inhibitors and mammalian target of rapamycin (mTOR) inhibitors-and programmed death 1 (PD-1) inhibitors has transformed the management of renal cell carcinoma (RCC). Once considered fatal, with a median survival of approximately 1 year, these agents have nearly tripled overall survival and have raised hopes of a possible cure for advanced RCC. This review begins with a brief discussion of the seminal von Hippel-Lindau/hypoxia-inducible factor axis in RCC...
December 2016: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28210563/neoadjuvant-therapy-for-treatment-of-breast-cancer-the-way-forward-or-simply-a-convenient-option-for-patients
#16
COMMENT
Abhishek Chatterjee, John K Erban
The complexity of managing early stage breast cancer is well known. Optimal treatment is increasingly multidisciplinary and in the modern era informed by sophisticated molecular tools to help select and guide therapy. Major phase III trials have determined that the order of systemic therapy relative to surgery does not influence important endpoints such as event free survival and overall survival (OS), but questions remain as to how best to utilize these most essential services. For example, there is still uncertainty regarding the ideal timing, intensity, and duration of proposed therapy...
February 2017: Gland Surgery
https://www.readbyqxmd.com/read/28208958/radiological-and-histopathological-outcome-of-giant-cell-tumor-of-femur-with-denosumab-treatment-a-case-report
#17
Preethi Dileep Menon, R Krishnakumar, Annie Jojo
Giant Cell Tumour of Bone (GCTB) is a benign but locally aggressive osteolytic skeletal neoplasm of young adults consisting of giant cells expressing RANK (Receptor Activator of Nuclear Factor-κB) and mesenchymal spindle-like stromal cells expressing RANKL (RANK ligand). The interaction of these cells leads to bone resorption. Recently, the RANKL inhibitor, denosumab, has demonstrated activity against giant-cell tumours. The current article reports a case of a Giant cell tumour of left distal femur with pathological fracture...
December 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28205193/new-therapeutic-strategies-for-triple-negative-breast-cancer
#18
REVIEW
Borbála Székely, Andrea L M Silber, Lajos Pusztai
Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer (TNBC) since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options such as immune checkpoint inhibitors and antibody-drug conjugates. Evidence also increasingly supports that platinum drugs and inhibitors of poly (ADP-ribose) polymerase, or PARP, are particularly effective in the treatment of germline BRCA-mutant cancers, including TNBC...
February 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28198176/what-is-changing-in-the-surgical-treatment-of-gastrointestinal-stromal-tumors-after-multidisciplinary-approach-a-comprehensive-literature-s-review
#19
Belinda De Simone, Luca Ansaloni, Massimo Sartelli, Federico Coccolini, Salomone Di Saverio, Maria A Pantaleo, Maristella Saponara, Margherita Nannini, Harishine K Abongwa, Josephine A Napoli, Fausto Catena
INTRODUCTION: GIST represent the most common mesenchymal neoplasms of the gastrointestinal tract Surgery is the only curative treatment for GIST. The aim of our review is to highlight the changes in the surgical treatment of GIST after the introduction of TKI therapy in a multimodality management ( neo-adiuvant or adiuvant setting). EVIDENCE ACQUISITION: We carried out a review of the recent literature about surgical treatment of GIST according to its anatomical location and size according to PRISMA STATEMENT to systematic review...
February 14, 2017: Minerva Chirurgica
https://www.readbyqxmd.com/read/28197838/the-growing-role-of-cdk4-6-inhibitors-in-treating-hormone-receptor-positive-advanced-breast-cancer
#20
REVIEW
Ami N Shah, Massimo Cristofanilli
Single-agent endocrine therapy has been the standard therapeutic choice for the management of hormone receptor (HR)-positive, Her2-negative advanced breast cancer (ABC) for decades. However, the rapidly accumulating data regarding the biological role and safety of CDK4/6 inhibitors and the first-in-class approval of palbociclib have made these novel agents an essential component of treatment for HR-positive ABC. In the frontline setting, palbociclib in combination with endocrine therapy showed an improvement in progression-free survival (PFS) by 10 months to nearly 25 months when compared with endocrine therapy alone and a clinical benefit rate (CBR = stable disease >24 weeks + partial response + complete response) of 85%...
January 2017: Current Treatment Options in Oncology
keyword
keyword
97139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"